Emergency loan keeps biotech firm afloat – crucial to staying operational
The Biotech company Acesion Pharma has taken up a Covid-19 emergency loan worth DKK 20m from the Danish Growth Fund to keep the engines running. An important phase II study has been postponed by at least six months, according to the firm's executive chairman.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
The Copenhagen-based Biotech Acesion Pharma has requested – and received – an emergency loan worth DKK 20m from the Danish Growth Fund, which will keep the company afloat during the Covid-19 pandemic.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
